chromosome 5 open reading frame 46Genealiases: AP-64 · SSSP1
Q-omics provides the consensus-scored C5orf46 profile across patient tissues and cancer cell-line models. C5orf46 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C5orf46 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, C5orf46 RNA expression shows 16,886 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where C5orf46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C5orf46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C5orf46 survival associations across molecular data types. C5orf46 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C5orf46 RNA expression–survival associations across cancer types. High C5orf46 expression shows unfavorable associations in HNSC, MESO, KIRP, CESC and KICH, but favorable associations in DLBC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C5orf46 RNA expression.
This table summarizes C5orf46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C5orf46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C5orf46 shows higher tumor expression in KIRC, BLCA, LUSC, LUAD, COAD and LIHC. The KIRC box plot shows higher C5orf46 RNA expression in tumor versus normal tissue (log2 FC = +4.912, t-test p < 0.001).
This table shows molecular features associated with C5orf46 in patient tissues and cancer cell lines. In patient samples, C5orf46 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, C5orf46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
